POXEL fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Poxel SA is a clinical-stage biopharmaceutical company, which engages in the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as non-alcoholic steatohepatitis (NASH). Its drug candidates include Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH. The company was founded by Sébastien Bolze, Sophie Hallakou-Bozec, Pascale Fouqueray-Grellier, Pascale Malgouyres, and Thomas Kuhn on March 6, 2009 and is headquartered in Lyon, France.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
POXEL does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company